MA51919A1 - Forme cristalline du tetrachlorhydrate de triethylenetetramine et utilisation pharmaceutique correspondante - Google Patents
Forme cristalline du tetrachlorhydrate de triethylenetetramine et utilisation pharmaceutique correspondanteInfo
- Publication number
- MA51919A1 MA51919A1 MA51919A MA51919A MA51919A1 MA 51919 A1 MA51919 A1 MA 51919A1 MA 51919 A MA51919 A MA 51919A MA 51919 A MA51919 A MA 51919A MA 51919 A1 MA51919 A1 MA 51919A1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline form
- triethylenetetramine
- tetrachlorhydrate
- pharmaceutical use
- corresponding pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/84—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne une nouvelle forme cristalline du tétrachlorure de triéthylènetétramine qui a une stabilité améliorée à température ambiante par rapport à des formes connues et au sel de dichlorure. La nouvelle forme cristalline est caractérisée en ce qu'elle présente des pics dans un spectre xrpd à 22,9, 25,4, 25,8, 26,6, 34,6 et 35,3 ± 0,1°2t et des décalages raman de 943, 1173, 1527 et 1612 ± 5 cm-1. La forme cristalline du tétrachlorure de triéthylènetétramine est utile dans le traitement de la maladie de wilson. L'invention concerne également un procédé de préparation d'une forme cristalline de tétrachlorure de triéthylènetétramine comprenant l'ajout d'un anti-solvant à une solution aqueuse du composé.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18290048 | 2018-05-04 | ||
| PCT/EP2019/061441 WO2019211464A1 (fr) | 2018-05-04 | 2019-05-03 | Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51919A1 true MA51919A1 (fr) | 2021-11-30 |
Family
ID=62455418
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51919A MA51919A1 (fr) | 2018-05-04 | 2019-05-03 | Forme cristalline du tetrachlorhydrate de triethylenetetramine et utilisation pharmaceutique correspondante |
| MA58726A MA58726B1 (fr) | 2018-05-04 | 2019-05-03 | Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA58726A MA58726B1 (fr) | 2018-05-04 | 2019-05-03 | Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US10988436B2 (fr) |
| EP (2) | EP4613337B1 (fr) |
| JP (2) | JP7679294B2 (fr) |
| KR (2) | KR20250121158A (fr) |
| CN (3) | CN111479798B (fr) |
| AR (1) | AR115080A1 (fr) |
| AU (2) | AU2019263969B2 (fr) |
| CA (1) | CA3096423A1 (fr) |
| CO (1) | CO2020013806A2 (fr) |
| DE (1) | DE19724752T1 (fr) |
| DK (1) | DK3652145T3 (fr) |
| EA (1) | EA202092241A1 (fr) |
| ES (1) | ES2769049T3 (fr) |
| FI (1) | FI3652145T3 (fr) |
| HR (1) | HRP20251307T1 (fr) |
| LT (1) | LT3652145T (fr) |
| MA (2) | MA51919A1 (fr) |
| PL (1) | PL3652145T3 (fr) |
| PT (1) | PT3652145T (fr) |
| RS (1) | RS67287B1 (fr) |
| SA (1) | SA520420467B1 (fr) |
| SG (1) | SG11202010785UA (fr) |
| SI (1) | SI3652145T1 (fr) |
| SM (1) | SMT202500387T1 (fr) |
| TW (1) | TWI902661B (fr) |
| WO (1) | WO2019211464A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019263969B2 (en) | 2018-05-04 | 2024-08-01 | Orphalan | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
| KR102489293B1 (ko) * | 2020-10-15 | 2023-01-17 | (주) 에프엔지리서치 | 공업용 등급의 트리에틸렌테트라민의 고순도 정제 방법 |
| US20240382435A1 (en) | 2021-04-26 | 2024-11-21 | Orphalan S.A. | Non-ceruloplasmin bound copper level monitoring |
| TWI819502B (zh) * | 2022-02-23 | 2023-10-21 | 裕捷股份有限公司 | 一種三伸乙基四胺四氫氯化物及其製備方法與組合物 |
| CN116675607A (zh) * | 2022-02-23 | 2023-09-01 | 裕捷股份有限公司 | 一种三亚乙基四胺四氢氯化物及其制备方法与组合物 |
| EP4558486A1 (fr) * | 2022-07-19 | 2025-05-28 | Biophore India Pharmaceuticals Pvt. Ltd | Procédé de préparation de la forme cristalline a du tétrachlorhydrate de n,n'-bis(2-aminoéthyl)-1,2-éthanediamine |
| EP4487839A1 (fr) | 2023-07-03 | 2025-01-08 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Forme pharmaceutique comprenant du tétrahydrochlorure de trientine et son procédé de préparation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1078731A (fr) | 1976-12-16 | 1980-06-03 | Charles E. Frosst And Co. | Kit de radiographie des os, utilisant le triethylene tetramine hexa (acide methylenephosphonique) |
| CS197093B1 (cs) * | 1978-06-16 | 1980-04-30 | Ivo Kuhr | Způsob přípravy čistého dihydrochloridu triethylentetraminu |
| DE19724752A1 (de) | 1997-04-24 | 1998-11-05 | Boehringer Mannheim Gmbh | Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von Entzündungen und Wunden der Haut |
| MXPA00009705A (es) | 1998-04-03 | 2003-07-14 | Univ Manitoba | Uso de poliaminas en el tratamiento de sintomas dermatologicos. |
| JP4369003B2 (ja) | 2000-02-23 | 2009-11-18 | ハリマ化成株式会社 | ハンダ付け用フラックス |
| CN1649577A (zh) | 2002-03-08 | 2005-08-03 | 普罗特米克斯公司 | 预防和/或治疗心血管疾病和/或相关的心衰 |
| AU2003222513A1 (en) | 2002-03-08 | 2003-09-22 | Protemix Corporation Limited | Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure |
| WO2004017957A1 (fr) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee |
| NZ545724A (en) | 2003-03-18 | 2007-11-30 | Protemix Corp Ltd | Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure |
| PT1778618E (pt) | 2004-07-19 | 2014-03-04 | Philera New Zealand Ltd | Síntese de trietilenotetraminas |
| CN106278907B (zh) * | 2014-12-17 | 2019-06-21 | 四川科瑞德凯华制药有限公司 | 一种盐酸曲恩汀化合物 |
| JP6326477B2 (ja) | 2015-12-25 | 2018-05-16 | 三洋化成工業株式会社 | 高分子凝集剤 |
| AU2019263969B2 (en) * | 2018-05-04 | 2024-08-01 | Orphalan | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
| WO2020006027A1 (fr) | 2018-06-29 | 2020-01-02 | Sharp Laboratories Of America, Inc. | Conception ultra fiable de canal physique de commande de liaison montante (pucch) de nouvelle radio (nr) de 5e génération (5g) |
| CN109076617B (zh) | 2018-07-25 | 2022-08-19 | 北京小米移动软件有限公司 | Mtc系统的随机接入方法、装置及存储介质 |
| TWI819502B (zh) | 2022-02-23 | 2023-10-21 | 裕捷股份有限公司 | 一種三伸乙基四胺四氫氯化物及其製備方法與組合物 |
-
2019
- 2019-05-03 AU AU2019263969A patent/AU2019263969B2/en active Active
- 2019-05-03 SI SI201930969T patent/SI3652145T1/sl unknown
- 2019-05-03 KR KR1020257025951A patent/KR20250121158A/ko active Pending
- 2019-05-03 KR KR1020207035089A patent/KR102843554B1/ko active Active
- 2019-05-03 PT PT197247521T patent/PT3652145T/pt unknown
- 2019-05-03 CN CN201980006492.6A patent/CN111479798B/zh active Active
- 2019-05-03 WO PCT/EP2019/061441 patent/WO2019211464A1/fr not_active Ceased
- 2019-05-03 DE DE19724752.1T patent/DE19724752T1/de active Pending
- 2019-05-03 FI FIEP19724752.1T patent/FI3652145T3/fi active
- 2019-05-03 EP EP25183948.6A patent/EP4613337B1/fr active Active
- 2019-05-03 EA EA202092241A patent/EA202092241A1/ru unknown
- 2019-05-03 SG SG11202010785UA patent/SG11202010785UA/en unknown
- 2019-05-03 HR HRP20251307TT patent/HRP20251307T1/hr unknown
- 2019-05-03 PL PL19724752.1T patent/PL3652145T3/pl unknown
- 2019-05-03 TW TW108115436A patent/TWI902661B/zh active
- 2019-05-03 JP JP2021510544A patent/JP7679294B2/ja active Active
- 2019-05-03 CN CN202210100454.0A patent/CN114394904A/zh active Pending
- 2019-05-03 EP EP19724752.1A patent/EP3652145B1/fr active Active
- 2019-05-03 CA CA3096423A patent/CA3096423A1/fr active Pending
- 2019-05-03 SM SM20250387T patent/SMT202500387T1/it unknown
- 2019-05-03 DK DK19724752.1T patent/DK3652145T3/da active
- 2019-05-03 RS RS20251018A patent/RS67287B1/sr unknown
- 2019-05-03 MA MA51919A patent/MA51919A1/fr unknown
- 2019-05-03 ES ES19724752T patent/ES2769049T3/es active Active
- 2019-05-03 MA MA58726A patent/MA58726B1/fr unknown
- 2019-05-03 LT LTEPPCT/EP2019/061441T patent/LT3652145T/lt unknown
- 2019-05-03 CN CN202411423442.7A patent/CN119306616A/zh active Pending
- 2019-05-06 AR ARP190101194A patent/AR115080A1/es unknown
-
2020
- 2020-06-30 US US16/917,266 patent/US10988436B2/en active Active
- 2020-11-03 SA SA520420467A patent/SA520420467B1/ar unknown
- 2020-11-04 CO CONC2020/0013806A patent/CO2020013806A2/es unknown
-
2021
- 2021-02-09 US US17/171,358 patent/US11072577B2/en active Active
- 2021-02-09 US US17/171,347 patent/US11117855B2/en active Active
- 2021-08-10 US US17/398,408 patent/US20220169594A1/en not_active Abandoned
-
2023
- 2023-11-03 US US18/386,906 patent/US12358861B2/en active Active
-
2024
- 2024-10-30 AU AU2024227767A patent/AU2024227767A1/en active Pending
- 2024-11-14 US US18/948,050 patent/US12358862B2/en active Active
- 2024-11-29 JP JP2024208197A patent/JP2025037978A/ja active Pending
-
2025
- 2025-06-18 US US19/242,394 patent/US20250382257A1/en active Pending
- 2025-09-08 US US19/322,234 patent/US20260055049A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51919A1 (fr) | Forme cristalline du tetrachlorhydrate de triethylenetetramine et utilisation pharmaceutique correspondante | |
| ES2551898T3 (es) | Derivado de benceno o tiofeno y su uso como inhibidor de la enzima VAP-1 | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| CA2489209A1 (fr) | Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique | |
| EA200100841A1 (ru) | Оксаминовые кислоты и их производные в качестве лигандов тиреоидных рецепторов | |
| MA43605B1 (fr) | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci | |
| CA2206794A1 (fr) | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament | |
| JP2016513663A5 (fr) | ||
| HU201537B (en) | Process for producing 2-chloro-5-chloromethylthiazole | |
| UY26769A1 (es) | Derivados nitrilos de beta aminoacidos | |
| MA39688B1 (fr) | Composés hétéroaryle pour le traitement de maladies ophtalmiques | |
| CA3037554A1 (fr) | Procede de preparation d'acides (1r,3r)- et (1s,3s)-2,2-dihalo-3-(phenyle substitue) cyclopropanecarboxylique | |
| TN2009000018A1 (fr) | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques | |
| HUP0200358A2 (hu) | Eljárás (2R)-2-propil-oktánsav előállítására | |
| ATE491453T1 (de) | Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges | |
| CA2519110A1 (fr) | Derives du benzenesulfonamide, leur procede de preparation et leur utilisation dans le traitement de la douleur | |
| Dajek et al. | trans-1, 2-Diaminocyclohexane-based sulfonamides as effective hydrogen-bonding organocatalysts for asymmetric Michael–hemiacetalization reaction | |
| JPWO1999011640A1 (ja) | エポキシコハク酸アミド誘導体 | |
| DK142413B (da) | Analogifremgangsmåde til fremstilling af 1-acyloxymethyl-5-fluoruracilderivater. | |
| FR3037953B1 (fr) | Procede de synthese de molecules portant une fonction oxyde de nitrile | |
| FR3111354B1 (fr) | Composition fluorescente comprenant au moins un composé de type benzazole pour la sécurisation de produits | |
| JP2008201740A (ja) | エダラボンの精製方法及び高純度エダラボン | |
| KR19980703485A (ko) | 에폭시숙신산 유도체 | |
| FR3100461B1 (fr) | Procédé de purification d’hydrofluorocarbures | |
| RU2663899C1 (ru) | Способ получения 1-карбамоилметил-4-фенил-2-пирролидона |